It looks as if we have a sighting of that rare Washington, D.C., unicorn: bipartisan agreement in the halls of Congress. Democrats and Republicans have united in defense of Big Pharma and are lobbying the Obama administration and State Department to pressure India's generic-drug policies.
In this video, health-care analyst David Williamson discusses what has Congress riled up, the importance of India as a growth driver for the pharma industry, and whether investors need to start taking precautions with their portfolios.
Follow David on Twitter: @MotleyDavid.
